Co-Authors
This is a "connection" page, showing publications co-authored by Marcus Shaker and John Oppenheimer.
Connection Strength
2.185
-
Reply to "How important is the second dose of the COVID-19 mRNA vaccine?" J Allergy Clin Immunol Pract. 2021 06; 9(6):2537-2539.
Score: 0.237
-
The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis. J Allergy Clin Immunol Pract. 2021 07; 9(7):2556-2561.
Score: 0.235
-
The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World. J Allergy Clin Immunol Pract. 2021 04; 9(4):1438-1441.
Score: 0.232
-
Reply to "Challenges to pediatric services during COVID-19 pandemic: A London, UK perspective". J Allergy Clin Immunol Pract. 2020 09; 8(8):2835-2836.
Score: 0.222
-
Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times. J Allergy Clin Immunol Pract. 2020 Jul - Aug; 8(7):2310-2321.e4.
Score: 0.220
-
Reply to "Subcutaneous terbutaline as an alternative to aerosolized albuterol". J Allergy Clin Immunol Pract. 2020 Jul - Aug; 8(7):2450-2452.
Score: 0.220
-
Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and Unusual Challenges for the Allergist/Immunologist. J Allergy Clin Immunol Pract. 2020 06; 8(6):1781-1790.e3.
Score: 0.219
-
COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic. J Allergy Clin Immunol Pract. 2020 05; 8(5):1477-1488.e5.
Score: 0.218
-
Simulation of Health and Economic Benefits of Extended Observation of Resolved Anaphylaxis. JAMA Netw Open. 2019 10 02; 2(10):e1913951.
Score: 0.211
-
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract. 2021 10; 9(10):3546-3567.
Score: 0.059
-
The Challenges and Opportunities for Shared Decision Making Highlighted by COVID-19. J Allergy Clin Immunol Pract. 2020 09; 8(8):2474-2480.e1.
Score: 0.056
-
A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services. J Allergy Clin Immunol Pract. 2020 Jul - Aug; 8(7):2125-2134.
Score: 0.055